What top creators are saying about Ultragenyx Pharmaceutical Inc.(RARE)

The bullish case cited rare-disease expertise, revenue, approved drugs, and a broad pipeline; concerns included heavy R&D spending and execution.

A speaker was bullish on Ultragenyx as a potential value idea, citing revenue and a broad pipeline while acknowledging R&D spending and concerns about business judgment.

A participant was favorable about its rare-disease focus, revenue, pipeline, and approved drugs, while noting heavy R&D spending and unsuccessful development efforts. The potential to double was a personal view without a timeframe.

The speaker cited revenue, its rare-disease pipeline, and founder experience as positives, while flagging heavy R&D spending and uneven project outcomes.

Included as a higher-beta biotech example to examine, without a company-specific conclusion.

The speaker said he was bullish, but provided no supporting thesis or catalyst.

The host cited Ultragenyx favorably as an example of a value-oriented investment.

Received FDA approval for Sanfilippo treatment; long-term bullish outlook targeting commercialization upside or a potential buyout at $30 to $40 within a year on post-approval pullbacks.

Experienced a sharp upward price spike moving toward $14 driven by FDA approval for its Sanfilippo syndrome treatment.

Viewed as extremely undervalued with a strong management track record and high optimism for upcoming FDA approval of its Sanfilippo syndrome gene therapy candidate.

Maintains a significant long position in deeply undervalued stock supported by FDA approvals and potential acquisition upside.

Viewed as a high-conviction value opportunity trading at ~2x sales with ~$750M in revenue after an overdone 47% sell-off on clinical trial news.

Bullish post-pullback buying opportunity following a failed Angelman trial, as core underlying pipeline assets remain undervalued.

The speaker holds a neutral stance, believing the stock was 'fairly valued' with no significant upside or downside at the time of analysis.

A bearish short-term catalyst occurred when the company did not stop its key study early for an interim analysis, which was perceived as a negative development for the trial's outcome.